JP2023504196A5 - - Google Patents
Info
- Publication number
- JP2023504196A5 JP2023504196A5 JP2022534239A JP2022534239A JP2023504196A5 JP 2023504196 A5 JP2023504196 A5 JP 2023504196A5 JP 2022534239 A JP2022534239 A JP 2022534239A JP 2022534239 A JP2022534239 A JP 2022534239A JP 2023504196 A5 JP2023504196 A5 JP 2023504196A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- cell
- peripheral blood
- cells
- blood mononuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943760P | 2019-12-04 | 2019-12-04 | |
| US62/943,760 | 2019-12-04 | ||
| US201962944349P | 2019-12-05 | 2019-12-05 | |
| US62/944,349 | 2019-12-05 | ||
| US202063035432P | 2020-06-05 | 2020-06-05 | |
| US63/035,432 | 2020-06-05 | ||
| PCT/US2020/063473 WO2021113759A1 (en) | 2019-12-04 | 2020-12-04 | Placenta-derived allogeneic car-t cells and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023504196A JP2023504196A (ja) | 2023-02-01 |
| JP2023504196A5 true JP2023504196A5 (https=) | 2024-04-09 |
Family
ID=74068688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534239A Pending JP2023504196A (ja) | 2019-12-04 | 2020-12-04 | 胎盤由来の同種ｃａｒ－ｔ細胞およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250092363A1 (https=) |
| EP (1) | EP4069258A1 (https=) |
| JP (1) | JP2023504196A (https=) |
| KR (1) | KR20220110199A (https=) |
| CN (1) | CN115397442A (https=) |
| AU (1) | AU2020397953A1 (https=) |
| BR (1) | BR112022010887A2 (https=) |
| CA (1) | CA3161789A1 (https=) |
| IL (1) | IL293462A (https=) |
| MX (1) | MX2022006704A (https=) |
| PH (1) | PH12022551367A1 (https=) |
| WO (1) | WO2021113759A1 (https=) |
| ZA (1) | ZA202205286B (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| RU2021118125A (ru) * | 2014-12-29 | 2022-04-06 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| AU2016249005B2 (en) * | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US20200087681A1 (en) * | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| KR20210111244A (ko) * | 2018-11-30 | 2021-09-10 | 셀룰래리티 인코포레이티드 | 태반-유래 동종이계 car-t 세포 및 이의 용도 |
-
2020
- 2020-12-04 IL IL293462A patent/IL293462A/en unknown
- 2020-12-04 JP JP2022534239A patent/JP2023504196A/ja active Pending
- 2020-12-04 CA CA3161789A patent/CA3161789A1/en active Pending
- 2020-12-04 BR BR112022010887A patent/BR112022010887A2/pt not_active Application Discontinuation
- 2020-12-04 CN CN202080084124.6A patent/CN115397442A/zh active Pending
- 2020-12-04 EP EP20829756.4A patent/EP4069258A1/en not_active Withdrawn
- 2020-12-04 MX MX2022006704A patent/MX2022006704A/es unknown
- 2020-12-04 PH PH1/2022/551367A patent/PH12022551367A1/en unknown
- 2020-12-04 KR KR1020227018403A patent/KR20220110199A/ko active Pending
- 2020-12-04 WO PCT/US2020/063473 patent/WO2021113759A1/en not_active Ceased
- 2020-12-04 US US17/830,865 patent/US20250092363A1/en active Pending
- 2020-12-04 AU AU2020397953A patent/AU2020397953A1/en not_active Abandoned
-
2022
- 2022-05-12 ZA ZA2022/05286A patent/ZA202205286B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3749753B1 (en) | Methods for manufacturing t cells | |
| CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
| Boissel et al. | Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells | |
| Marktel et al. | Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation | |
| Pittari et al. | Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies | |
| Tey et al. | Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation | |
| Tonn et al. | Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Zhang et al. | Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance | |
| Lamb Jr et al. | γδ T cells: a new frontier for immunotherapy? | |
| TWI410495B (zh) | 新穎之人類ｔ細胞群 | |
| Xu et al. | Toward precision manufacturing of immunogene T-cell therapies | |
| JP2022522231A (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| CN102459577A (zh) | 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法 | |
| Yu et al. | Revolution of CAR engineering for next-generation immunotherapy in solid tumors | |
| EP2702145A1 (en) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells | |
| Peragine et al. | Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients | |
| Takahashi et al. | Dendritic cells generated from human blood in granulocyte macrophage-colony stimulating factor and interleukin-7 | |
| Van Elssen et al. | NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? | |
| Lu et al. | CD16+ CD56− NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft‐versus‐leukemia effect | |
| Wang et al. | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context | |
| DiGiusto et al. | Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials | |
| Lankester et al. | Will post-transplantation cell therapies for pediatric patients become standard of care? | |
| Sahin et al. | Natural killer cell-mediated cellular therapy of hematological malignancies |